11/19/2026 | Press release | Distributed by Public on 11/19/2026 15:31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): October 21, 2026 |
Fractyl Health, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
Delaware |
001-41942 |
27-3553477 |
||
|
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
3 Van de Graaff Drive Suite 200 |
||||
|
Burlington, Massachusetts |
01803 |
|||
|
(Address of Principal Executive Offices) |
(Zip Code) |
|||
|
Registrant's Telephone Number, Including Area Code: (781) 902-8800 |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
||
|
Common Stock, $0.00001 par value per share |
GUTS |
The Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory Note
This Amendment No. 1 on Form 8-K/A (this "Amendment") amends the Current Report on Form 8-K filed by Fractyl Health, Inc. (the "Company") with the Securities and Exchange Commission on October 22, 2026 (the "Original Form 8-K"), which reported, among other things, the retirement of Jay Caplan as the Company's President and Chief Product Officer. This Amendment is being filed to disclose the material terms of the Separation Agreement and Release (the "Separation Agreement") and the consulting agreement (the "Consulting Agreement") entered into by Mr. Caplan and the Company following the filing of the Original Form 8-K, and to file the Separation Agreement and the Consulting Agreement as exhibits. Except as set forth herein, this Amendment does not amend, modify or update any other disclosure contained in the Original Form 8-K, and this Amendment should be read in conjunction with the Original Form 8-K.
Retirement of Executive Officer
As previously disclosed on October 22, 2026, effective as of October 30, 2026, Jay Caplan retired from the Company as its President and Chief Product Officer.
In connection with Mr. Caplan's retirement, on November 16, 2026, Mr. Caplan and the Company entered into the Separation Agreement. Subject to the Separation Agreement becoming effective following expiration of the applicable revocation period and Mr. Caplan's continued compliance with his restrictive covenant obligations, Mr. Caplan will receive (i) cash payments of $515,000, equal to 12 months of his annual base salary, payable in accordance with the Company's normal payroll schedule and (ii) up to 12 months of Company-paid COBRA continuation coverage. The Separation Agreement includes a release of claims.
In addition, on November 19, 2026, Mr. Caplan and the Company entered into the Consulting Agreement, effective as of October 31, 2026, pursuant to which Mr. Caplan will provide consulting services to the Company during this transition for an initial term of six months from the effective date, pursuant to which the Company will pay Mr. Caplan an hourly rate of $250.00 for the time spent performing such services, subject to a cap of 40 hours per month and any withholding required by applicable law. The Consulting Agreement does not guarantee any minimum level of services and may be terminated for convenience by the Company on 30 days' prior written notice or by Mr. Caplan on 60 days' prior written notice.
Copies of the Separation Agreement and Consulting Agreement are attached hereto as Exhibit 10.1 and Exhibit 10.2, respectively. The above descriptions of the material terms of the Separation Agreement and Consulting Agreement do not purport to be complete and are qualified in their entirety by reference to the applicable Exhibit.
(d) Exhibits
|
Exhibit No. |
Description |
|
|
10.1 |
Separation Agreement and Release by and between Fractyl Health, Inc. and Jay Caplan dated November 16, 2026 |
|
|
10.2 |
Consulting Agreement by and between Fractyl Health, Inc. and Jay Caplan effective October 31, 2026 |
|
|
104 |
Cover Page Interactive Data File (embedded within the inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Fractyl Health, Inc. |
|||
|
Date: |
November 19, 2026 |
By: |
/s/ Harith Rajagopalan |
|
Harith Rajagopalan, M.D., Ph.D. |